Literature DB >> 24477623

Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness.

Emmanuel Chautard1, Zangbéwendé Guy Ouédraogo, Julian Biau, Pierre Verrelle.   

Abstract

Gathering evidence has revealed that Akt signaling pathway plays an important role in glioma progression and aggressiveness. Among Akt kinases the most studied, Akt1, has been involved in many cellular processes that are in favor of cell malignancy. More recently, the actions of the two other isoforms, Akt2 and Akt3 have emerged in glioma. After a description of Akt pathway activation, we will explore the role of each isoform in malignant glioma that strengthens the current preclinical and clinical studies evaluating the impact of Akt pathway targeting in glioblastomas.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24477623     DOI: 10.1007/s11060-014-1382-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  113 in total

1.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

Authors:  Evanthia Galanis; Jan C Buckner; Matthew J Maurer; Jeffrey I Kreisberg; Karla Ballman; J Boni; Josep M Peralba; Robert B Jenkins; Shaker R Dakhil; Roscoe F Morton; Kurt A Jaeckle; Bernd W Scheithauer; Janet Dancey; Manuel Hidalgo; Daniel J Walsh
Journal:  J Clin Oncol       Date:  2005-07-05       Impact factor: 44.544

2.  MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.

Authors:  Yan Cheng; Yi Zhang; Li Zhang; Xingcong Ren; Kathryn J Huber-Keener; Xiaoyuan Liu; Lei Zhou; Jason Liao; Heike Keihack; Li Yan; Eric Rubin; Jin-Ming Yang
Journal:  Mol Cancer Ther       Date:  2011-11-04       Impact factor: 6.261

3.  North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.

Authors:  Jann N Sarkaria; Evanthia Galanis; Wenting Wu; Patrick J Peller; Caterina Giannini; Paul D Brown; Joon H Uhm; Steven McGraw; Kurt A Jaeckle; Jan C Buckner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-09-23       Impact factor: 7.038

4.  Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines.

Authors:  K Nakatani; D A Thompson; A Barthel; H Sakaue; W Liu; R J Weigel; R A Roth
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

5.  Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.

Authors:  D Haas-Kogan; N Shalev; M Wong; G Mills; G Yount; D Stokoe
Journal:  Curr Biol       Date:  1998-10-22       Impact factor: 10.834

6.  The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

Authors:  Arnab Chakravarti; Gary Zhai; Yoshiyuki Suzuki; Sormeh Sarkesh; Peter M Black; Alona Muzikansky; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

7.  Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.

Authors:  Jie Lin; Deepak Sampath; Michelle A Nannini; Brian B Lee; Michael Degtyarev; Jason Oeh; Heidi Savage; Zhengyu Guan; Rebecca Hong; Robert Kassees; Leslie B Lee; Tyler Risom; Stefan Gross; Bianca M Liederer; Hartmut Koeppen; Nicholas J Skelton; Jeffrey J Wallin; Marcia Belvin; Elizabeth Punnoose; Lori S Friedman; Kui Lin
Journal:  Clin Cancer Res       Date:  2013-01-03       Impact factor: 12.531

8.  Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells.

Authors:  Gary L Gallia; Betty M Tyler; Christine L Hann; I-Mei Siu; Vincent L Giranda; Angelo L Vescovi; Henry Brem; Gregory J Riggins
Journal:  Mol Cancer Ther       Date:  2009-02-10       Impact factor: 6.261

9.  Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation.

Authors:  Gary D Kao; Zibin Jiang; Anne Marie Fernandes; Anjali K Gupta; Amit Maity
Journal:  J Biol Chem       Date:  2007-05-18       Impact factor: 5.157

10.  Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.

Authors:  Ulrik Lassen; Morten Sorensen; Tine Bernhardtsen Gaziel; Benedikte Hasselbalch; Hans Skovgaard Poulsen
Journal:  Anticancer Res       Date:  2013-04       Impact factor: 2.480

View more
  25 in total

1.  MiR-212-3p inhibits glioblastoma cell proliferation by targeting SGK3.

Authors:  Huailei Liu; Chenguang Li; Chen Shen; Fei Yin; Kaikai Wang; Yaohua Liu; Bingjie Zheng; Weiguang Zhang; Xu Hou; Xin Chen; Jianing Wu; Xiaoxiong Wang; Chen Zhong; Jiakang Zhang; Huaizhang Shi; Jing Ai; Shiguang Zhao
Journal:  J Neurooncol       Date:  2015-02-27       Impact factor: 4.130

2.  MRI virtual biopsy and treatment of brain metastatic tumors with targeted nanobioconjugates: nanoclinic in the brain.

Authors:  Rameshwar Patil; Alexander V Ljubimov; Pallavi R Gangalum; Hui Ding; Jose Portilla-Arias; Shawn Wagner; Satoshi Inoue; Bindu Konda; Arthur Rekechenetskiy; Alexandra Chesnokova; Janet L Markman; Vladimir A Ljubimov; Debiao Li; Ravi S Prasad; Keith L Black; Eggehard Holler; Julia Y Ljubimova
Journal:  ACS Nano       Date:  2015-05-06       Impact factor: 15.881

3.  Advances in Imaging: Brain Tumors to Alzheimer's Disease.

Authors:  Rameshwar Patil; Yosef Koronyo; Alexander V Ljubimov; Brenda Salumbides; Adam Mamelak; Pallavi R Gangalum; Hui Ding; Jose Portilla-Arias; Eggehard Holler; Pramod Butte; Maya Koronyo-Hamaoui; Julia Y Ljubimova; Keith L Black
Journal:  Bangk Med J       Date:  2015-09

4.  Mitochondrial energy metabolism and signalling in human glioblastoma cell lines with different PTEN gene status.

Authors:  Marina Comelli; Ivan Pretis; Alessia Buso; Irene Mavelli
Journal:  J Bioenerg Biomembr       Date:  2017-12-06       Impact factor: 2.945

5.  Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B.

Authors:  Xuexia Zhou; Run Wang; Xuebing Li; Lin Yu; Dan Hua; Cuiyun Sun; Cuijuan Shi; Wenjun Luo; Chun Rao; Zhendong Jiang; Ying Feng; Qian Wang; Shizhu Yu
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

6.  Fangchinoline suppresses the growth and invasion of human glioblastoma cells by inhibiting the kinase activity of Akt and Akt-mediated signaling cascades.

Authors:  Bingyu Guo; Peng Xie; Jingyuan Su; Tingting Zhang; Xiaoming Li; Guobiao Liang
Journal:  Tumour Biol       Date:  2015-09-25

7.  AQP9 promotes astrocytoma cell invasion and motility via the AKT pathway.

Authors:  Yao Lv; Qiang Huang; Weimin Dai; Yuanqing Jie; Guofeng Yu; Xiaofeng Fan; An Wu; Qian Miao
Journal:  Oncol Lett       Date:  2018-08-23       Impact factor: 2.967

8.  An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes.

Authors:  Kumarasamypet M Mohankumar; David S Currle; Elsie White; Nidal Boulos; Jason Dapper; Christopher Eden; Birgit Nimmervoll; Radhika Thiruvenkatam; Michele Connelly; Tanya A Kranenburg; Geoffrey Neale; Scott Olsen; Yong-Dong Wang; David Finkelstein; Karen Wright; Kirti Gupta; David W Ellison; Arzu Onar Thomas; Richard J Gilbertson
Journal:  Nat Genet       Date:  2015-06-15       Impact factor: 38.330

9.  AEG-1-AKT2: A novel complex controlling the aggressiveness of glioblastoma.

Authors:  Luni Emdad; Bin Hu; Swadesh K Das; Devanand Sarkar; Paul B Fisher
Journal:  Mol Cell Oncol       Date:  2015-01-23

Review 10.  NFAT5-Mediated Signalling Pathways in Viral Infection and Cardiovascular Dysfunction.

Authors:  Guangze Zhao; Sana Aghakeshmiri; Yankuan T Chen; Huifang M Zhang; Fione Yip; Decheng Yang
Journal:  Int J Mol Sci       Date:  2021-05-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.